Current treatment options for colon cancer peritoneal carcinomatosis

Tomoyoshi Aoyagi, Krista P Terracina, Ali Raza, Kazuaki Takabe

Abstract
Peritoneal carcinomatosis (PC), the dissemination of cancer cells throughout the lining of the abdominal cavity, is the second most common presentation of colon cancer distant metastasis. Despite remarkable advances in cytotoxic chemotherapy and targeted therapy for colon cancer over the last 15 years, it has been repeatedly shown that these therapies remain ineffective for colon cancer PC. Recently, there has been a rapid accumulation of reports that cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) prolongs the life of colon cancer PC patients. Here, we will review the clinical presentation, the mechanisms of disease progression, and current treatment options for colon cancer peritoneal carcinomatosis, with a focus on the benefits and limitations of CRS-HIPEC.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

Key words: Cancer; Colorectal; Carcinomatosis; Peritoneal; Hyperthermic intraperitoneal chemotherapy; Intraperitoneal chemotherapy; Cytoreductive surgery; Mechanism

Core tip: This paper aims to review the clinical presentation, the mechanisms of disease progression, and current treatment options for colon cancer peritoneal carcinomatosis, with a focus on the benefits and limitations of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy.

INTRODUCTION
The most critical and ultimately life threatening feature of malignant disease is its ability to metastasize to other organs[1-4]. The peritoneum is second only to the liver as a site for colon cancer metastasis. Approximately 4%-7% of patients with colon cancer are noted to have peritoneal carcinomatosis (PC) at the time of diagnosis, despite recent advances in early detection of the disease[5-9]. Although the tumors are primarily confined to the peritoneum with no discernable metastasis elsewhere in approximately 20%-25% of patients with colon cancer PC[10-12], the prognosis of these patients is poor with a median survival of 6-9 mo after diagnosis[7,9,13]. As a result, until recent years, colon cancer PC had been regarded as a form of systemic metastasis portending a terminal state of colon cancer for which only palliative surgery (such as diverting colostomy) and/or systemic chemotherapy was recommended[13-16]. Here, we will review the presentation, mechanisms of disease progression, and current treatment options of colon cancer PC, which have been reported to prolong life of those patients.
The symptoms of colon cancer PC can vary and are nonspecific; many patients, however, experience extreme fatigue, abdominal discomfort, and abdominal pain because of ascites and associated bowel obstruction\(^{19,20}\). If ascites is present, cytology from aspirated fluid can help to establish the diagnosis in half of these patients. Approximately 40% of the patients can be diagnosed by imaging modalities including computed tomography (CT), magnetic resonance imaging, positron emission tomography (PET) and ultrasound, but in 8% of the patients, colon cancer PC is found at the time of laparotomy\(^{21}\). In many cases diagnostic laparoscopy can be helpful to gain more detailed information on the intraperitoneal dissemination of the tumor or histological confirmation of the suspicion of PC\(^{22}\). PC rates are highest among women, patients with primary mucinous adenocarcinomas, tumor stage T4, lymph node stage N2, and among patients with a positive resection margin\(^{23}\). Time to recurrent disease has been reported with a median time of 14-16 mo\(^{24,25}\). In terms of PC, median time to diagnosis of metachronous disease was 18 mo\(^{23}\).

MECHANISM OF ESTABLISHMENT AND PROGRESSION OF COLON CANCER PC

The multistep process through which PC is established has been conceptualized to include the five following steps (Figure 1)\(^{23,26}\).

**Release of loose cancer cells from the primary tumor into the abdominal cavity**

In order for the cancer cell to disseminate in the abdominal cavity, it needs to be released from the primary colon cancer mass. This process can occur through several mechanisms including spontaneous and/or iatrogenic exfoliation of cancer cells from the primary tumor. In colon cancer PC, the expressions and/or the functions of cell-cell adhesion molecules, such as E-cadherin, can be down-regulated thereby promoting cancer cell detachment\(^{27-29}\). Iatrogenic causes include incomplete resection, inadvertent breach of the tumor’s integrity, or transection...
of blood or lymph vessels with subsequent leakage\textsuperscript{[30]}. 

**Transport in abdominal cavity**

Once the cancer cells are released into the abdominal cavity, they are transported to different anatomical regions of the abdomen governed by gravity, peristaltic gastrointestinal movement, and the mechanics of the negative pressure generated by movement of the diaphragm\textsuperscript{[31]}. The most common sites of disease localization include the right lower quadrant, the right diaphragm, the hepatic-duodenal ligament, the omentum, the pelvic viscerum and the parietal peritoneum\textsuperscript{[32]}.

**Adhesion to the peritoneum**

In order for the floating cancer cells to establish PC, the cells need to adhere to the peritoneum. Evidence suggests that inflammation plays a major role in this process by enhancing expression of adhesion molecules. Adhesion of cancer cells to the mesothelial layer is mediated by adhesion molecules, such as vascular cell adhesion molecule 1 (VCAM-1 (CD106)), intercellular adhesion molecule 1 (ICAM-1 (CD54)), and platelet endothelial cell adhesion molecule (PECAM-1 (CD31)), many of which are also expressed by endothelial cells\textsuperscript{[33,34]}. Pro-inflammatory mediators, IL-1\(\beta\), IL-6 and the epidermal growth factor, have been shown to increase peritoneal adhesion of cancer cells\textsuperscript{[35,37]}. TNF-\(\alpha\) has been shown to enhance the expression of ICAM-1\textsuperscript{[38]}.

Adhesive interactions have also been reported between the mesothelial hyaluronan coat and the transmembrane glycoprotein CD44, a molecule expressed by many cancer types\textsuperscript{[39]}. The mechanisms responsible for this site specificity remain incompletely understood, but may relate to the pro-angiogenic environment elicited by the dense capillary network surrounding these immune aggregates\textsuperscript{[40]}.

**Invasion into the submesothelial layers**

Loose cancer cells gain access to submesothelial tissue at areas of peritoneal discontinuity. The cells themselves may precipitate these areas of weakness in the peritoneum, as cancer cells have been shown to induce apoptosis of mesothelial cells by a FAS dependent mechanism\textsuperscript{[41]}. Alternatively, the extracellular matrix might become exposed by contraction of mesothelial cells and disruption of intercellular junctions in response to inflammatory mediators\textsuperscript{[42]}. Invasion of the submesothelial tissue is accompanied by adhesion to and degradation of the existing extracellular matrix through various integrins and proteases respectively\textsuperscript{[43]}.

**Access to the systemic circulation**

Once the submesothelial stroma is invaded, cancer cells can then gain access to the blood and lymphatic microcirculation. Particulate matter, including free peritoneal cancer cells, can enter the systemic circulation through subperitoneal lymphatic lacunae located between the muscle fibers of the diaphragm\textsuperscript{[44]}. The peritoneum layering the pouch of Douglas, for example, is rich in subperitoneal lymphatic vessels and milky spots. Intrapertoneal fluid containing free cancer cells, once reaching the pelvic subperitoneal lymphatics, then travels toward the rectum, and finally flows into the lymph nodes around the iliac artery. In contrast, the peritoneum covering the liver, as well as the serosal surface of small bowel and spleen, are devoid of lymphatic stomata and milky spots and thus are involved in systemic dissemination of cancer cells only in the late stage of PC\textsuperscript{[45]}.

**TREATMENT OPTIONS AND OUTCOMES**

**Systemic chemotherapy**

PC has been considered to be a form of systemic distant metastasis and a terminal state in colon cancer, thus historically palliative systemic chemotherapy was utilized. The few retrospective studies examining this palliative therapy invariably show disappointing responses to systemic chemotherapy by 5-fluorouracil (5-FU) and leucovorin with a poor prognosis compared to other metastatic sites\textsuperscript{[33,34,36-40]}. Recently, more effective cytotoxic chemotherapies and biologic targeted therapies using oxaliplatin, irinotecan, bevacizumab, cetuximab, or panitumumab have been reported to improve the survival of patients with metastatic colon cancer. However, since the majority of patients involved in these studies are those with liver or lung metastases, the effects of these agents on PC remain unclear\textsuperscript{[40,41]}. Only a few papers have described the outcome of systemic chemotherapy for colon cancer PC. A pooled analysis of north central cancer treatment group phase III trials N9741 and N9841 demonstrates that current systemic chemotherapy, such as 5-FU based combination therapy, FOLFOX, is not effective for PC and fails to significantly improve survival\textsuperscript{[42]}.

**Intraperitoneal chemotherapy**

Intrapertoneal delivery of anti-neoplastic agents for cancer into the abdominal cavity has been attempted since antiquity. In the mid-18\textsuperscript{th} century, English surgeon Christopher Warrik injected a mixture of “Bristol water” and “Claret” (a Bordeaux wine) into the peritoneal cavity of a woman suffering from intractable ascites\textsuperscript{[43]}. Following the discovery of the anti-neoplastic potential of nitrogen mustard, its effect in the abdominal cavity was studied within the mid-20\textsuperscript{th} century\textsuperscript{[45]}. Approximately one in five patients with colon cancer harbors minimal residual disease in the peritoneum after surgical resection, while PC develops in approximately one in seven patients\textsuperscript{[45]}. This observation led to a hypothesis that intraperitoneal chemotherapy following complete resection of a T3 or T4 stage colon cancer may decrease peritoneal recurrence. In animal models of colon cancer, intraperitoneal administration of chemotherapeutic drugs successfully prevented tumor development following colon cancer cell implantation into abdominal cavity\textsuperscript{[54]}. Clinical studies, however, have thus far not shown any benefit from adjuvant intraperitoneal...
chemotherapy for colon cancer. Vaillant et al\textsuperscript{[59]} randomized 267 stage II and III colon cancer patients to either surgery alone or surgery combined with intraoperative intravenous 5-FU and postoperative intraperitoneal 5-FU administration. Overall, adjuvant 5-FU failed to improve disease free survival (DFS), overall survival, or the frequency of peritoneal recurrence. An unplanned subgroup analysis indicated a DFS benefit in patients with stage II disease. Similarly, a randomized trial by Nordlinger et al\textsuperscript{[60]} failed to show any benefit from immediate postoperative regional chemotherapy (intraperitoneal or intraportal administration by the choice of participating center) followed by intravenous chemotherapy compared with intravenous chemotherapy alone in patients with resected stage II or III colorectal cancer. Taken together, neither of these two trials were able to show any decrease in peritoneal recurrence from adjuvant intraperitoneal chemotherapy in patients with colorectal cancer.

Early postoperative intraperitoneal chemotherapy

Early postoperative intraperitoneal chemotherapy (EPIC) is infusion of chemotherapy directly into the abdominal cavity through ports, allowing circulation and/or drainage of the drugs for one to five days after cytoreductive surgery (CRS) to kill remaining microscopic cancerous tumors and free floating cells. EPIC may be given in multiple cycles for several months after surgery.

In 1995, a French group attempted to conduct a randomized controlled clinical trial comparing CRS plus EPIC to systemic chemotherapy, but it was rapidly abandoned because of patients’ dissatisfaction with the treatment in the control arm. Subsequently, a modified clinical trial comparing CRS plus EPIC versus CRS without EPIC was initiated in 1996. This study by Elias et al\textsuperscript{[57]} closed prematurely after 4 years in 2000 with only 35 of the required 90 patients enrolled. In this incomplete trial, EPIC failed to demonstrate any survival benefit; however, analysis of these 35 patients showed that complete CRS (CCR-0) resulted in a 2-year survival rate of 60%, an impressive improvement from the historic 10% survival rate among patients treated with systemic chemotherapy and palliative surgery\textsuperscript{[57]}.

Mahteme et al\textsuperscript{[58]} compared 18 colon cancer PC patients who underwent CRS, EPIC (5-FU, cisplatin, or irinotecan) and systemic 5-FU based chemotherapy with 18 matched control patients who underwent systemic chemotherapy alone. Patients in the CRS group had a median survival of 32 mo, with 2-year and 5-year survival of 60% and 28%, respectively, whereas patients in the control group had a median survival of 14 mo, with 2-year and 5-year survival of 10% and 5%, respectively (\(P = 0.01\), vs CRS group). Glehen et al\textsuperscript{[59]} analyzed a multi-institutional registry (28 international institutions) involving 506 colorectal cancer PC patients who underwent CRS and EPIC with a median follow-up of 53 mo, finding a median survival of 19 mo, and 1-, 3- and 5-year survival to be 72%, 39% and 19%, respectively. Two hundred seventy-one patients had CCR-0 and their median survival was 32 mo, with 1-, 3- and 5-year survival of 87%, 47% and 31%, respectively. The details of CRS and chemotherapy regimens differed among the institutions, limiting the conclusions that can be drawn from this study\textsuperscript{[59]}. A systematic review by Yan et al\textsuperscript{[60]} confirmed the importance of achieving CCR-0, as it was determined that those procedures that succeeded in this fashion resulted in improved survival to 60 from 28 mo when compared with procedures leaving residual disease. CCR-0 resulted in prolonged overall survival from 22% to 49% at 5 years. The overall quality of the available evidence is, however, rather low, and a potentially serious postoperative complication rate should be taken into account. A consistent finding is that optimal results can be expected in patients with a limited disease burden in whom a complete resection can be achieved.

Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy

Recently, Cytoreductive Surgery combined with Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) has been introduced for colorectal cancer PC, which appears to be the most effective approach for prolonging survival in selected patients\textsuperscript{[49,59,61-63]}. CRS-HIPEC is a type of hyperthermic therapy used in combination with direct application of chemotherapy inside the abdominal cavity after surgical removal of as much cancer as possible. HIPEC is also known as intraperitoneal hyperthermic chemoperfusion, intra-abdominal hyperthermic chemoperfusion, or intraoperative chemo hyperthermia peritoneal perfusion. In this procedure, warmed anti-cancer drugs are infused and circulated in the abdominal cavity in direct contact with the peritoneum. These procedures last as long as 8-10 h and carry a significant rate of complications. According to the National Cancer Institute database, currently there are eight ongoing clinical trials worldwide that include HIPEC as a keyword; 2 phase II, 4 phase II, and 2 phase I trials (from www.cancer.gov, consulted 26th of June 2013)\textsuperscript{[64]}.

Verwaal et al\textsuperscript{[49,60,68]} reported 105 patients with colon cancer PC without evidence of hematogenous metastases enrolled between 1998 and 2001, and randomly allocated to receive CRS-HIPEC followed by IV 5-FU and leucovorin vs 5-FU and leucovorin with or without palliative surgery. The median disease specific survival was 22.2 mo in the CRS-HIPEC arm and 12.6 mo in the control arm (\(P = 0.028\)). The survival was significantly better in patients with no more than five of seven abdominal PC regions and in patients in whom a macroscopic complete resection (CCR-0) was achieved. Unfortunately, the value of this randomized clinical trial is limited by the fact that the systemic chemotherapy regimen was not the standard of care (which includes Irinotecan and/or Oxaliplatin), appendiceal \((n = 18)\) and rectal \((n = 12)\) tumors were not balanced in the two groups, and the HIPEC protocol was based only on mitomycin C in the perfusate. In order to assess the effect of CRS-HIPEC with modern systemic chemotherapies, Elias et al\textsuperscript{[60]} conducted...
a comparison of the survival of patients with isolated and resectable PC treated with systemic chemotherapy containing oxaliplatin or irinotecan or treated with CRS-HIPEC. In this study, the patients treated with modern systemic chemotherapy achieved a median survival of 24 mo, while median survival was 63 mo with a 5-year survival rate of 51% after CRS-HIPEC.

Franko et al. compared 67 patients treated with mitomycin C-based HIPEC to 38 controls, with all 105 patients receiving 5-FU, irinotecan, oxaliplatin and bevacizumab or cetuximab. Unfortunately, in this study the number of patients with liver metastases and the number receiving oxaliplatin and targeted therapies were both greater in the HIPEC group (78% vs 18% and 59% vs 18% respectively).

Among non-randomized, retrospective multi-institutional studies, the largest published series comes from the French registry and includes 523 patients with colorectal cancer PC from 1990 to 2007 treated with CRS-HIPEC. Despite the fact that 16% of patients had incomplete CRS with macroscopic residuals (CCR-1), making it difficult to extrapolate data about survival, and that the large number of participating centers adds variability (relating to learning curve and surgical standardization), the reported 30-d mortality was only 3%, which was remarkably lower than that reported in the Dutch trial (8%)\[^{[69]}\]. Since PC without systemic spread is found in 3% of patients with colorectal cancer, this subgroup might benefit from CRS-HIPEC. In regards to long-term survival, complete cytoreduction (CCR-0) appears to be critical given the results from a multinational retrospective analysis of 506 patients with CRC treated with CRS-HIPEC showing an overall median survival of 32.4 mo with CCR-0 scores compared to 19 mo with suboptimal resection\[^{[69]}\]. Multivariate analysis revealed that other variables associated with survival include treatment by a second procedure, limited disease extent, age less than 65 years, and use of adjuvant chemotherapy.

One randomized trial and several prospective cohort studies have shown improvements in disease-free and overall survival associated with CRS-HIPEC with/without EPIC when compared to palliative-intent surgery and/or systemic chemotherapy\[^{[65-67,69]}\]. Chua et al.\[^{[69]}\] enrolled 294 patients, comparing supportive care and palliation with postoperative systemic chemotherapy based on 5-FU, irinotecan, oxaliplatin, Capetcitabine and monoclonal antibodies, with or without HIPEC (low-dose mitomycin C) and EPIC (high dose 5-FU). The type of perioperative intraperitoneal chemotherapy did not have an effect on survival (median survival HIPEC = 36 mo, EPIC =38 mo, HIPEC and EPIC = 43 mo; \(P = 0.715\)). On the other hand, the rate of grade III/IV complications was reported to be significantly higher when HIPEC was combined with EPIC, especially in patients with a high total tumor burden. Thus, the use of EPIC in combination with CRS-HIPEC is associated with an increased rate of complications\[^{[69]}\].

Since the total tumor burden of PC is critical to predicting the outcome of CRS-HIPEC, several scoring methods have been proposed in an effort to quantify both the extent of peritoneal disease and the completeness of resection. The peritoneal cancer index (PCI, Washington Cancer Institute), first described by Sugarbaker in 1996, is commonly used for quantification. The scores range from 0 to 39 and can be determined prior to surgery using CT images\[^{[71,72]}\]. The PCI is semi-quantitative, aiming to define and measure the peritoneal involvement. It is easily reproducible and has been validated by several studies and by expert consensus\[^{[73-76]}\]. Other scores have been reported that attempt to preoperatively differentiate between patients that might benefit from curative or palliative therapy such as the Peritoneal Surface Disease Severity Score\[^{[69]}\]. It is extremely important to select appropriate patients with colorectal PC for CRS-HIPEC, though the perioperative mortality is reduced at high-volume centers with extensive experience in the procedure, morbidity remains high regardless\[^{[77]}\]. Also Segelman et al.\[^{[78]}\] reported predicting the individual risk of metachronous PC after surgery for non-metastatic CC. The models may help in the planning of treatment and follow-up of patients.

Although currently the most common chemotherapeutic agents infused during HIPEC are mitomycin-C and cisplatin, the drug regimen differs considerably between institutions. The intraperitoneal application of cetuximab is a new treatment option. This tri-functional antibody which is active against the EpCAM-antigen of the peritoneal tumor cells has been proven to be effective in the treatment of malignant ascites and is licensed for this indication. It is possible that morbidity and effectiveness of CRS-HIPEC may be improved as knowledge and technology continue to develop leading to new drugs, more effective patient selection, and improved perioperative management.

### FUTURE DIRECTIONS

Peritoneal carcinomatosis historically has been regarded as an untreatable disease and despite advances, remains a significant challenge for oncologists and surgeons. For many years, patients with PC have been considered to be beyond the realm of curative therapy, but in recent years promising results have been reported in a variety of tumor types using CRS-HIPEC. A randomized trial has demonstrated a significant survival gain compared with palliative therapy alone in colorectal cancer PC. However, CRS-HIPEC is only available in specialized institutions and is not indicated for the majority of colorectal PC patients due to its high morbidity and mortality. Furthermore, many clinicians continue to have reservations about recommending patients to undergo such a highly morbid procedure with a goal of prolonging life for median of 10 mo, especially given that any expectation of curing PC remains unrealistic. Likewise, CRS-HIPEC has no effect on alleviating systemic symptoms such as cachexia, weight loss, and malnutrition that significantly hinder the remaining quality of life. Further
elucidating the biological behavior of colon PC and developing molecularly targeted therapy may serve as an avenue of future research.

REFERENCES

1. House MG, Ito H, Gönen M, Fong Y, Allen PJ, DeMatteo RP, Brennan MF, Blumgart LH, Jarnagin WR, D’Angelica MI. Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution. J Am Coll Surg 2010; 210:744-752, 752-755 [PMID: 20421043 DOI: 10.1016/j.jamcollsur.2009.12.040]

2. Kanap GP, Taylor A, Primrose JN, Langeberg WJ, Kelsh MA, Mowat FS, Alexander DD, Choti MA, Poston G. Survival after resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors. Clin Epidemiol 2012; 4:283-301 [PMID: 23152705 DOI: 10.2147/CLEP.S34285]

3. Spolverato G, Eja J, Azad N, Pawlik TM. Surgery for colorectal liver metastases: The evolution of determining prognosis. World J Gastrointest Oncol 2013; 5:207-221 [PMID: 24363329 DOI: 10.4251/wjgo.v5.i2.207]

4. Go PH, Klaassen Z, Meadows MC, Chamberlain RS. Gastrointestinal cancer and brain metastasis: a rare and ominous sign. Cancer 2011; 117:3630-3640 [PMID: 21319152 DOI: 10.1002/cncr.29340]

5. Villeneuve PJ, Sundaresan RS. Surgical management of colorectal lung metastasis. Clin Colon Rectal Surg 2009; 22:235-241 [PMID: 19357814 DOI: 10.1055/s-0029-1242463]

6. Li WH, Peng JJ, Xiang JQ, Chen W, Cai SJ, Zhang W. Oncological outcome of unresectable lung metastases without extrapulmonary metastases in colorectal cancer. Lung Cancer 2012; 74:207-221 [PMID: 22071567 DOI: 10.1016/j.lungcan.2011.11.001]

7. Segelman J, Granath F, Holm T, Machado M, Mahteme H, Martling A. Incidence, prevalence and risk factors for peri-tonsilar carcinomatosis from colorectal cancer. Br J Surg 2012; 99:699-705 [PMID: 22287157 DOI: 10.1002/bjs.8679]

8. Jayne DG, Fook S, Lot C, Seow-Choen F. Peritoneal carcino-omatosis from colorectal cancer. Br J Surg 2002; 89:1545-1550 [PMID: 1245564 DOI: 10.1046/j.1365-2168.2002.02274.x]

9. Minsky BD, Mies C, Rich TA, Recht A, Chaffey JT. Potentially curative surgery of colon cancer: patterns of failure and survival. J Clin Oncol 1988; 6:106-118 [PMID: 2826711]

10. Russell AH, Tong D, Dawson LE, Wisbeck WM, Griffin TW, Laramore GE, Luk HK. Adenocarcinoma of the retroperitoneal ascending and descending colon: sites of initial dissemination and clinical patterns of recurrence following surgery alone. Int J Radiat Oncol Biol Phys 1983; 9:361-365 [PMID: 6841189]

11. Tong D, Russell AH, Dawson LE, Wisbeck WM, Griffin TW, Laramore GE, Luk HK. Adenocarcinoma of the cecum: natural history and clinical patterns of recurrence following radical surgery. Int J Radiat Oncol Biol Phys 1983; 9:357-360 [PMID: 6841188]

12. Sadeghi B, Arvieux C, Glehen O, Abouard AC, Rivoire M, Baulieux J, Fontaumard E, Brachet A, Caillot JL, Faure JL, Porcheron J, Peix JL, François Y, Vignal J, Gilly FN. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer 2000; 88:358-363 [PMID: 10640968]

13. Elias D, Blot F, El Otmany A, Antoun S, Lasser P, Boige V, Rougié P, Ducreux M. Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy. Cancer 2001; 92:71-76 [PMID: 11443611]

14. Sugarbaker PH. Surgical management of carcinomatosis from colorectal cancer. Clin Colon Rectal Surg 2005; 18:190-203 [PMID: 16131302 DOI: 10.1055/s-2005-861280]

15. Fiori E, Lamazza A, De Cesare A, Bononi M, Volpino P, Schillaci A, Cavallaro A, Cangemi V. Palliative management of malignant rectosigmoidal obstruction. Coloscopy vs. endoscopic stenting. A randomized prospective trial. Anticancer Res 2004; 24:265-268 [PMID: 15015606]

16. Sugarbaker PH. Review of a personal experience in the management of carcinomatosis and sarcomatosis. Jpn J Clin Oncol 2001; 31:573-583 [PMID: 11902837]

17. Blair SL, Chu DZ, Schwarz RE. Outcome of palliative operations for malignant bowel obstruction in patients with peritoneal carcinomatosis from nongynecological cancer. Ann Surg Oncol 2001; 8:632-637 [PMID: 11569777]

18. Ceelen WP, Flessner MF. Intrapерitoneal therapy for peri- tonsal tumors: biophysics and clinical evidence. Nat Rev Clin Oncol 2010; 7:108-115 [PMID: 20010898 DOI: 10.1038/nrclinonc.2009.217]

19. Piso P, Arnold D. Multimodal treatment approaches for peri- tonsal carcinosis in colorectal cancer. Tisch Arztebl Int 2011; 108:802-808 [PMID: 22190994 DOI: 10.3238/arztebl.2011.0802]

20. Berhelot C, Morel O, Girault S, Verrière V, Poirier AL, Mor- roch J, Boucher Y, Le Jeune J, Lorimier G. Use of FDG-PET/ CT for peritoneal carcinomatosis before hyperthermic intra- peritoneal chemotherapy. Nutr Med Commun 2011; 32:23-29 [PMID: 21042225 DOI: 10.1097/MMN.0b013e328354f730]

21. van TD, Morris DL, Shigeki K, Dario B, Marcello D. Pre- operative investigations in the management of peritoneal surface malignancy with cyoreductive surgery and peri- operative intraperitoneal chemotherapy: Expert consensus statement. J Surg Oncol 2008; 98:224-227 [PMID: 18726681 DOI: 10.1002/jso.21069]

22. van Gestel YR, Thomassen I, Lemmens VE, Puijit JF, van Herk-Sukel MP, Rutten HJ, Creemers GJ, de Hingh IH. Metachronous peritoneal carcinomatosis after curative treatment of colorectal cancer. Eur J Surg Oncol 2014; 40:963-969 [PMID: 24183168 DOI: 10.1016/j.ejso.2013.10.001]

23. Galandiuk S, Wierand HS, Moertel CG, Cha SS, Fitzgibbons RJ, Pemberton JH, Wolf BG. Patterns of recurrence after cura- tive resection of the colon and rectum. Surg Gynecol Obstet 1992; 174:27-32 [PMID: 1729745]

24. Ceelen WP, Bracke ME. Peritoneal minimal residual disease in colorectal cancer: mechanisms, prevention, and treatment. Lancet Oncol 2004; 5:72-79 [PMID: 15111247 DOI: 10.1016/S1470-2045(07)70358-8]

25. Ceelen W, Van Nieuwenhove Y, Pattyn P. Surgery and in- tracavitary chemotherapy for peritoneal carcinomatosis from colorectal origin. Acta Gastroenterol Belg 2008; 71:373-378 [PMID: 19317277]

26. Terauchi M, Kajiyama H, Yamashita M, Kato M, Tsukamoto H, Umezui T, Hosono S, Yamamoto E, Shibata K, Ino K, Nawa A, Nakagata T, Kikawa F. Possible involvement of TWIST in enhanced peritoneal metastasis of epithelial ovarian carcinoma. Clin Exp Metastasis 2007; 24:329-339 [PMID: 17487558 DOI: 10.1007/s10477-007-7090-1]

27. Kokenyesi R, Murray KP, Benshushan A, Huntley ED, Kao MS. Invasion of interstitial matrix by a novel cell line from primary peritoneal carcinosarcoma, and by established ovarian carcinoma cell lines: role of cell-matrix adhesion molecules, proteins, and E-cadherin expression. Gynecol Oncol 2003; 89:60-72 [PMID: 12694655]

28. Pocard M, Debruyne P, Bras-Gonçalves R, Mareel M, Dutril- lux B, Poupon MF. Single alteration of p53 or E-cadherin genes can alter the surgical resection benefit in an exper- imental model of colon cancer. Dis Colon Rectum 2001; 44:1106-1112 [PMID: 11535849]

29. Hansen E, Wolff N, Knuechel R, Ruschhoff J, Hofstaedter F, Taeger K. Tumor cells in blood shed from the surgical field.
31 Meyer MA. Distribution of intra-abdominal malignant seeding: dependency on dynamics of flow of ascitic fluid. J. Reintgenol Radion Ther Noc Med 1973; 119: 198-206 [PMID: 4744725]

32 Sugarbaker PH. Observations concerning cancer spread within the peritoneal cavity and concepts supporting an ordered pathophysiology. Cancer Treat Rev 1996; 22: 79-100 [PMID: 8849945]

33 Jonjic N, Peri G, Bernasconi S, Sciacca FL, Colotta F, Pellici P, Lanfrancione L, Mantovani A. Expression of adhesion molecules and chemotactic cytokines in cultured human mesothelial cells. J Exp Med 1992; 176: 1165-1174 [PMID: 1383357]

34 Bittinger F, Klein CL, Skarke C, Brochhausen C, Walgenbach S, Röhrig O, Köhler H, Kirkpatrick CJ. PECAM-1 expression in human mesothelial cells: an in vitro study. Pathobiology 1996; 64: 320-327 [PMID: 9159026]

35 van Grevenstein WM, Hofland LJ, van Rossem ME, van Koetsveld PM, Jeeke J, van Eijck CH. Inflammatory cytokines stimulate the adhesion of colon carcinoma cells to human mesothelial monolayers. Dig Dis Sci 2002; 47: 2775-2783 [PMID: 12739486 DOI: 10.1007/s10620-007-9778-4]

36 Ziprin P, Ridgway PF, Pfistermüller KL, Peck DH, Darzi A. Migration properties of the human ovarian adenocarcinoma cell line IGROV1: importance of alpha(v)beta3 in integrins and vitronectin. Cancer Res 2005; 65: 3830-3838 [PMID: 16064275 DOI: 10.1158/0008-5472.CAN-04-2749]

37 Klein CL, Bittinger F, Skarke CC, Wagner M, Köhler H, Walgenbach S, Kirkpatrick CJ. Effects of cytokines on the expression of cell adhesion molecules by cultured human omental mesothelial cells. Pathobiology 1995; 63: 204-212 [PMID: 8866792]

38 Cannistra SA, Kansas CS, Niloff J, DeFranzo B, Kim Y, Optsmeenier C. Binding of ovarian cancer cells to peritoneal mesothelium in vitro is partly mediated by CD44H. Cancer Res 1993; 53: 3830-3838 [PMID: 8339295]

39 Gerber SA, Rybalko VY, Bigelow CE, Lugade AA, Foster TH, Frelinger JG, Lord EM. Preferential attachment of peri toneal tumor metastases to omental immune aggregates and possible role of a unique vascular microenvironment in metastatic spread and growth. J Pathol 1995; 179: 1517-1525 [PMID: 8733046 DOI: 10.1002/path.1900179111]

40 Heath RM, Jayne DG, O’Leary R, Morrison EE, Guillou PJ. Tumour-induced apoptosis in human mesothelial cells: a mechanism of peritoneal invasion by Fas Ligand/Fas interaction. Br J Cancer 2004; 90: 1437-1442 [PMID: 15054668 DOI: 10.1038/sj.bjc.6601635]

41 Warn R, Harvey P, Warn A, Foley-Comer A, Heldin P, Vessnel M, Arakaki N, Daikuhara Y, Laurent CJ, Herrick SE, Mutsaers SE. HGF/SF induces mesothelial cell migration and proliferation by autocrine and paracrine pathways. Exp Cell Res 2001; 267: 258-266 [PMID: 11426944 DOI: 10.1006/excr.2001.52240]

42 Carreiras F, Rigot V, Cretu S, Andre F, Gauduchon P, Marvaldi J. Migration properties of the human ovarian adenocarcinoma cell line IGROV1: importance of alpha(v)beta3 in integrins and vitronectin. Int J Cancer 1999; 80: 285-294 [PMID: 9935212]

43 Abu-Hijleh MF, Habbal OA, Moqattash ST. The role of the diaphragm in lymphatic absorption from the peritoneal cavity. J Anat 1995; 186 (Pt 3): 453-467 [PMID: 7559120]

44 Kusumasa S, Baratti D, Zaffaroni N, Villa R, Laterza B, Balestra MR, Deraco M. Pathophysiology and biology of peritoneal carcinomatosis. World J Gastrointest Oncol 2010; 2: 12-18 [PMID: 21168012 DOI: 10.4251/wjgo.v2.i.12]

45 Chu DZ, Lang NP, Thompson C, Osteen PK, Westbrook KC. Peritoneal carcinomatosis in nongonococcal malignancy: A prospective study of prognostic factors. Cancer 1989; 63: 364-376 [PMID: 2918444]

46 Köhne CH, Cunningham D, Di Costanzo F, Glimelius B, Blüham G, Aranda E, Scheithauer W, Rouquier P, Palmer M, Wils J, Baron B, Pignatti F, Schöffski P, Micheels S, Hecker H. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol 2002; 13: 308-317 [PMID: 11886010]

47 Bloemendaal AL, Verwaal VJ, van Ruth S, Boot H, Zoetmulder FA. Conventional surgery and systemic chemotherapy for peritoneal carcinomatosis of colorectal origin: a prospective study. Eur J Surg Oncol 2005; 31: 1145-1151 [PMID: 16084051 DOI: 10.1016/j.ejso.2005.06.002]

48 Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, Zoetmulder FA. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2005; 23: 3737-3743 [PMID: 1551293 DOI: 10.1200/JCO.2003.04.187]

49 Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramana- than RK, Williamson SK, Findlay BP, Pitot HC, Alberts S. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial. J Clin Oncol 2006; 24: 3347-3353 [PMID: 16849748 DOI: 10.1200/JCO.2006.06.1317]

50 Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Grifffing S, Holmgen E, Ferrara N, Fyfe G, Rogers B, Ross K, Kabbainavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342 [PMID: 15175435 DOI: 10.1056/NEJMoa032691]

51 Franko J, Shi Q, Goldman CD, Pockaj BA, Nelson GD, Goldberg RM, Pitot HC, Grotehy A, Alberts SR, Sargent DJ. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of North central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol 2012; 30: 263-267 [PMID: 22162570 DOI: 10.1200/JCO.2011.37.21]

52 Weisberger AS, Levine B, Storaasli JP. Use of nitrogen mustard in treatment of serous effusions of neoplastic origin. J Am Med Assoc 1955; 159: 1704-1707 [PMID: 13271133]

53 Harbaschek A, Meyer F, Schneider-Stock R, Pross M, Ridwelski K, Lippert H. Comparison of intraperitoneal with intravenous administration of taxol in experimental peritoneal carcinomatosis. Chemotherapy 2007; 53: 410-417 [PMID: 17952200 DOI: 10.1159/000110005]

54 Vaillant JC, Nordlinger B, Deuffic S, Arnaud JP, Pelissier E, Favre JP, Jaedicke D, Fourtanier G, Grandjean J-P, Marze P, Letoublon C, Adjuvant intraperitoneal 5-fluorouracil in high-risk colon cancer: A multicenter phase III trial. Ann Surg 2000; 231: 449-456 [PMID: 10749603]

55 Nordlinger B, Rouquier P, Arnaud JP, Debois M, Wils J, Ol- lier JC, Grobost O, Lasser P, Wals J, Lacourt J, Seitz GP, Guimares dos Santos J, Bleiberg H, Mackiewicz R, Conroy T, Bouché O, Morin T, Biala L, van Cutsem E, Bedenne L. Adjuvant regional chemotherapy and systemic chemotherapy versus systemic chemotherapy alone in patients with stage II-III colorectal cancer: A multicentre randomised controlled phase III trial. Lancet Oncol 2005; 6: 459-468 [PMID: 15992694 DOI: 10.1016/S1470-2045(05)70222-9]

56 Elias D, Delperro JR, Sideris L, Benhamou E, Pocard M, Baron O, Giovannini M, Lasser P. Treatment of peritoneal carcinomatosis from colorectal cancer: impact of complete cytoreductive surgery and difficulties in conducting ran-
domized trials. *Ann Surg Oncol* 2004; 11: 518-521 [PMID: 15123461 DOI: 10.1245/ASO.2004.09.008]

58 Mahteme H, Hansson J, Berglund A, Pihlman L, Glimelius B, Nygren P, Graf W. Improved survival in patients with peritoneal metastases from colorectal cancer: a preliminary study. *Br J Cancer* 2004; 90: 403-407 [PMID: 14735184 DOI: 10.1038/sj.bjc.6603586]

59 Gleen O, Kwiatkowski F, Sugarbaker PH, Elias D, Levine EA, De Simone M, Barone R, Yonemura Y, Cavaliere F, Quenet F, Gutman M, Tentes AA, Lorimier G, Bernard JL, Bereder JM, Porcheron J, Gomez-Portilla A, Shen P, Deraco M, Rat F. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. *J Clin Oncol* 2004; 22: 3284-3292 [PMID: 15310771 DOI: 10.1200/JCO.2004.10.012]

60 Van TD, Black D, Savady R, Sugarbaker PH. Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for periitoneal carcinomatosis from colorectal carcinoma. *J Clin Oncol* 2006; 24: 4011-4019 [PMID: 16921055 DOI: 10.1200/JCO.2006.07.1142]

61 Verwaal VJ, van Ruth S, Witkamp A, Boot H, van Slooten G, Zoetmulder FA. Long-term survival of peritoneal carcinomatosis of colorectal origin. *Ann Surg Oncol* 2005; 12: 65-71 [PMID: 15827780 DOI: 10.1007/s10434-004-0116-z]

62 Königsrainer I, Beckert S. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: where are we? *World J Gastroenterol* 2012; 18: 5317-5320 [PMID: 22982046 DOI: 10.3748/wjg.v18.i35.5317]

63 Al-Shammaa HA, Li Y, Yonemura Y. Current status and future strategies of cytoreductive surgery plus perioperative hyperthermic hypercytotoxic chemotherapy for peritoneal carcinomatosis. *World J Gastroenterol* 2008; 14: 1159-1166 [PMID: 18300340]

64 Cocolini F, Gheda F, Lotti M, Virzi S, Isusco D, Ghermandi C, Melotti R, Baiocchi G, Giuliani SM, Ansaloni L, Catena F. Peritoneal carcinomatosis. *World J Gastroenterol* 2013; 19: 6979-6994 [PMID: 22422942 DOI: 10.3748/wjg.v19.i41.6979]

65 Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. *Ann Surg Oncol* 2008; 15: 2426-2432 [PMID: 18521686 DOI: 10.1245/s10434-008-9966-2]

66 Elias D, Lefevre H, Chevalier J, Brouquet A, Marchal F, Classe JM, Ferron G, Guilloit JM, Meeus P, Goëde R, Bonastre J. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for periitoneal carcinomatosis of colorectal origin. *J Clin Oncol* 2009; 27: 681-685 [PMID: 19103728 DOI: 10.1200/JCO.2008.19.7160]

67 Franko J, Ibrahim Z, Gusani NJ, Holtzman MP, Bartlett DL, Zeh HJ. Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis. *Cancer* 2010; 116: 3756-3762 [PMID: 20564081 DOI: 10.1002/cncr.25116]

68 Elias D, Gilly F, Boutittie F, Quenet F, Bereder JM, Mansvelt B, Lorimier G, Dubé P, Glehen O. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. *J Clin Oncol* 2010; 28: 63-68 [PMID: 19917863 DOI: 10.1200/JCO.2009.23.9288]

69 Chua TC, Morris DL, Saxena A, Esquivel J, Lianue W, Doerfer J, Germer CT, Kerscher AG, Pelz JO. Influence of modern systemic therapies as adjunct to cytoreduction and perioperative intraperitoneal chemotherapy for patients with colorectal peritoneal carcinomatosis: a multicenter study. *Ann Surg Oncol* 2011; 18: 1560-1567 [PMID: 21203904 DOI: 10.1245/s10434-010-1522-1]

70 McConnell YJ, Mack LA, Francis WP, Ho T, Temple WJ. HIPEC+EPIC versus HIPEC-alone: differences in major complications following cytoreduction surgery for peritoneal malignancy. *J Surg Oncol* 2013; 107: 591-596 [PMID: 23219533 DOI: 10.1002/jso.23276]

71 Sugarbaker PH, Jablonski KA. Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. *Ann Surg* 1995; 221: 124-132 [PMID: 7857141]

72 Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. *Cancer Treat Res* 1996; 82: 359-374 [PMID: 8849962]

73 Kianmanesh R, Scaringi S, Sabate JM, Castel B, Pons-Kerjean N, Coffin B, Hay JM, Flament Y, Msika S. Iterative cytoreductive surgery associated with hyperthermic intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis of colorectal origin with or without liver metastases. *Ann Surg 2007*; 245: 597-603 [PMID: 17414609 DOI: 10.1097/01.sla.0000255561.87771.11]

74 Glehen O, Cotte E, Schreiber V, Sayag-Beauchard AC, Vignal J, Gilly FN. Intraperitoneal chemohyperthermia and attempted cytoreductive surgery in patients with peritoneal carcinomatosis of colorectal origin. *Br J Surg* 2004; 91: 747-754 [PMID: 15164446 DOI: 10.1002/bjs.4473]

75 Portilla AG, Shigeki K, Dario B, Marcello D. The intraoperative staging systems in the management of peritoneal surface malignancy. *J Surg Oncol* 2008; 98: 228-231 [PMID: 18726882 DOI: 10.1002/jso.20168]

76 Rivard JD, McConnell YJ, Temple WJ, Mack LA. Cytoreduction and heated intraperitoneal chemotherapy for colorectal cancer: are we excluding patients who may benefit? *J Surg Oncol* 2014; 109: 104-109 [PMID: 24449172 DOI: 10.1002/jso.23446]

77 Gusani NJ, Cho SW, Colovos C, Seo S, Franko J, Richard SD, Edwards RP, Brown CK, Holtzman MP, Zeh HJ, Bartlett DL. Aggressive surgical management of peritoneal carcinomatosis with low mortality in a high-volume tertiary cancer center. *Ann Surg Oncol* 2008; 15: 754-763 [PMID: 18080166 DOI: 10.1245/s10434-007-0970-4]

78 Segelman J, Akre O, Gustafsson UO, Bottai M, Martling A. Individualized prediction of risk of metachronous peritoneal carcinomatosis of colorectal cancer. *Colorectal Dis* 2014; 16: 359-367 [PMID: 24410859 DOI: 10.1111/codi.12552]

79 Heiss MM, Murawa P, Koralessa P, Kutarska E, Kolesnik OO, Ivanchenko VV, Dudnichenko AS, Aleknaviciene B, Razbudauskas A, Gore M, Ganea-Motan E, Ciuleanu T, Wimbenger P, Schmittel A, Schmalfeldt B, Burges A, Boke Meyer C, Lindhofer H, Lahr A, Parsons SL. The functional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial. *Int J Cancer* 2010; 127: 2209-2221 [PMID: 20473913 DOI: 10.1002/ijc.25423]

80 Ströhlein MA, Lindford F, Rüttinger D, Grützner KU, Schermanski OC, Jäger M, Lindhofer H, Hennig M, Jauch KW, Peschel C, Heiss MM. Immunotherapy of peritoneal carcinomatosis with the antibody catumaxomab in colon, gastric, or pancreatic cancer: an open-label, multicenter, phase I/II trial. *Onkologie* 2011; 34: 101-108 [PMID: 21358214 DOI: 10.1159/000324667]

P- Reviewer: Roncucci L
S- Editor: Ma YJ L- Editor: A E- Editor: Liu XM
